Biopolymer-Based Nanosystem for Drug Delivery, 2nd Edition

Dear Colleagues,

The enhanced permeability and retention (EPR) effect was discovered more than three decades ago (Y. Matsumura, H. Maeda 1986). This discovery is now cited as sparkinf a new wave of nanomedicine-related innovations for tumor-targeted drug delivery, a new concept in cancer chemotherapy. As of now, more than 50 nanomedicine formulations have been approved for clinical use. In the anticancer agent class, the flagship formulation is the biopolymer-based drug Abraxane (nanoparticle albumin-bound paclitaxel). ADCs represent an anticancer class in which specific biopolymers serve as antibodies to target moieties when they are conjugated to a highly toxic warhead drug, making them an effective anticancer agent. These drugs combine chemotherapy and immunotherapy, providing improved patient outcomes. The encapsulation of other biopolymer ingredients, such as RNA and DNA, or, in other words, active biomacromolecular therapeutic agents, results in the formation of nanosystems. Nowadays, the priority is to develop new vaccines. Recently, nanoformulated vaccines saved the lives of hundreds millions of people during the COVID pandemic, a task that remains ongoing.

Researchers must find new appropriate biopolymers that are biodegradable, biocompatible, non-immunogenic, improve the bioavailability of active cargos, and protect the active ingredient in the bloodstream. Depending on the formulation involved, the nature of the release of the active ingredient is a key factor. The main value is the precise targetting of the “cargo” to the cancer cells and the avoidance of healthy cells. This goal can be achieved by developing nanoformulation systems. The economic strength of this subdivision within the pharmaceutical industry is well known. However, R&D innovation in the biotech sector requires more time and effort compared the required levels in other fields. This explains the necessity of considering the conclusions of a professional risk analysis.

Scientists are encouraged to send relevant research for submission in this Special Issue.

Prof. Dr. Ildikó Bácskay
Prof. Dr. János Borbély
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nano-formulations of drugs
• antibody drug conjugation (ADC)
• nanoformulated vaccines
• delivery of biologics
• biotech risk analysis
• assessment of biocompatibility
• drug delivery system formulation
• characterization of dosage forms
• in vitro dissolution studies
• SEDDS